ImmuSAFE COVID-19 biochip test

for quantitative determination of antibody levels and binding sites

Now available

FEATURED PRODUCTS

IMMUNOME Protein Array

High-throughput multiplexed autoantibody screening protein array containing 1600+
autoantigens

ImmuSAFE COVID Tests

Contains correctly folded antigens from SARS-CoV-2 and 25 other Corona and Influenza
viruses

SARS-CoV-2 Antigens

7 Recombinant SARS-CoV-2 antigens expressed using the patented KREX™ functional proteomics technology

What We Do

What We Do

  • Identify drug responders with >90% accuracy

  • Use our antigens to develop better vaccines and diagnostic tests

  • Diagnose cancer & autoimmune diseases 5 to 7 years earlier

  • Identify drug responders with >90% accuracy

  • Diagnose cancer & autoimmune diseases 5 to 7 years earlier

  • Use our antigens to develop better vaccines and diagnostic tests

Sengenics measures autoantibodies at unrivalled sensitivity and specificity

UPCOMING EVENTS

Dates for all events are to be confirmed because of the COVID-19 pandemic

KREX TECHNOLOGY

KREX™ utilises the BCCP folding marker to actively select for soluble, correctly folded, functional proteins

PARTNERING

Engage in innovative research, discovery and development through active long-term collaborations with us

DOWNLOADS

Resources to access our technology

FAQs

Your technical questions – answered

SOLUTIONS

One technology – endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2020© Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X